Carmustine
Bone Marrow Suppression; Pumonary Toxicity
- Use under supervision of experienced physician in the use of cancer chemotherapy
Bone Marrow suppression (notably thrombocytopenia & leukopenia)
- May contribute to bleeding and infections.
- Toxicity is cumulative, thus adjust dose based on nadir counts from prior doses.
- Do not repeat doses more frequently that every 6 weeks
- Perform weekly complete blood cell counts for at least six weeks post dose
Pulmonary Toxicity
- Dose related.
- Risk increases with cumulative doses > 1400 mg/m2, history of lung disease and duration of therapy. Delayed cases of pulmonary fibrosis have been reported years after administration in childhood.
Monitoring data
- Perform weekly complete blood cell counts for at least six weeks post dose
Patient counseling
Package inserts
Additional information
Updated: January 2018